Overview

PK of BV100 in Patients VABP Suspected or Confirmed to be Due to CRAB

Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB
Phase:
Phase 2
Details
Lead Sponsor:
BioVersys AG
Treatments:
Polymyxin B
Polymyxins